SENSUS HEALTHCARE INC (SRTS) Stock Fundamental Analysis
USA - NASDAQ:SRTS - US81728J1097 - Common Stock
3.2 USD
-0.11 (-3.32%)
3.2 USD
0 (0%)
Taking everything into account, SRTS scores 5 out of 10 in our fundamental rating. SRTS was compared to 191 industry peers in the Health Care Equipment & Supplies industry. SRTS has a great financial health rating, but its profitability evaluates not so good. SRTS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
SRTS had negative earnings in the past year.
In the past year SRTS had a positive cash flow from operations.
Of the past 5 years SRTS 4 years were profitable.
SRTS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SRTS has a better Return On Assets (-1.44%) than 70.16% of its industry peers.
Looking at the Return On Equity, with a value of -1.63%, SRTS is in the better half of the industry, outperforming 72.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.44% | ||
| ROE | -1.63% | ||
| ROIC | N/A |
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of SRTS has remained more or less at the same level.
In the last couple of years the Operating Margin of SRTS has grown nicely.
The Gross Margin of SRTS (52.19%) is comparable to the rest of the industry.
SRTS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SRTS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 52.19% |
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
2. Health
2.1 Basic Checks
SRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
SRTS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SRTS remains at a similar level compared to 5 years ago.
There is no outstanding debt for SRTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SRTS has an Altman-Z score of 6.54. This indicates that SRTS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.54, SRTS belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.54 |
ROIC/WACCN/A
WACC8.63%
2.3 Liquidity
A Current Ratio of 8.14 indicates that SRTS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.14, SRTS belongs to the top of the industry, outperforming 88.48% of the companies in the same industry.
SRTS has a Quick Ratio of 5.79. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.79, SRTS belongs to the top of the industry, outperforming 85.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.14 | ||
| Quick Ratio | 5.79 |
3. Growth
3.1 Past
SRTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -114.63%.
The Earnings Per Share has been growing by 18.56% on average over the past years. This is quite good.
Looking at the last year, SRTS shows a small growth in Revenue. The Revenue has grown by 3.29% in the last year.
The Revenue has been growing by 8.93% on average over the past years. This is quite good.
EPS 1Y (TTM)-114.63%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-160%
Revenue 1Y (TTM)3.29%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%-20.82%
3.2 Future
SRTS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.64% yearly.
Based on estimates for the next years, SRTS will show a quite strong growth in Revenue. The Revenue will grow by 14.67% on average per year.
EPS Next Y-172.42%
EPS Next 2Y-23.42%
EPS Next 3Y13.61%
EPS Next 5Y11.64%
Revenue Next Year-22.17%
Revenue Next 2Y7.08%
Revenue Next 3Y14.93%
Revenue Next 5Y14.67%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SRTS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 13.64, which indicates a correct valuation of SRTS.
Based on the Price/Forward Earnings ratio, SRTS is valued cheaply inside the industry as 87.96% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of SRTS to the average of the S&P500 Index (22.94), we can say SRTS is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 13.64 |
4.2 Price Multiples
91.10% of the companies in the same industry are more expensive than SRTS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.07 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SRTS's earnings are expected to grow with 13.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.42%
EPS Next 3Y13.61%
5. Dividend
5.1 Amount
SRTS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.2
-0.11 (-3.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners29.15%
Inst Owner Change0%
Ins Owners16.61%
Ins Owner Change0.02%
Market Cap52.61M
Analysts81.82
Price Target8.16 (155%)
Short Float %5.57%
Short Ratio5.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-443.8%
Min EPS beat(2)-561.36%
Max EPS beat(2)-326.24%
EPS beat(4)1
Avg EPS beat(4)-32.54%
Min EPS beat(4)-561.36%
Max EPS beat(4)786.28%
EPS beat(8)4
Avg EPS beat(8)32.29%
EPS beat(12)5
Avg EPS beat(12)8.22%
EPS beat(16)8
Avg EPS beat(16)22.58%
Revenue beat(2)1
Avg Revenue beat(2)-4.91%
Min Revenue beat(2)-22.89%
Max Revenue beat(2)13.08%
Revenue beat(4)3
Avg Revenue beat(4)13.83%
Min Revenue beat(4)-22.89%
Max Revenue beat(4)47%
Revenue beat(8)6
Avg Revenue beat(8)26.85%
Revenue beat(12)6
Avg Revenue beat(12)11.41%
Revenue beat(16)9
Avg Revenue beat(16)14%
PT rev (1m)0%
PT rev (3m)-27.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-208.33%
EPS NY rev (1m)-129.03%
EPS NY rev (3m)-358.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-41.37%
Revenue NY rev (1m)-2.03%
Revenue NY rev (3m)-27.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 13.64 | ||
| P/S | 1.4 | ||
| P/FCF | 15.07 | ||
| P/OCF | 14.75 | ||
| P/B | 1.01 | ||
| P/tB | 1.01 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.06
EYN/A
EPS(NY)0.23
Fwd EY7.33%
FCF(TTM)0.21
FCFY6.64%
OCF(TTM)0.22
OCFY6.78%
SpS2.28
BVpS3.17
TBVpS3.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.44% | ||
| ROE | -1.63% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 52.19% | ||
| FCFM | 9.3% |
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.73% | ||
| Cap/Sales | 0.2% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.14 | ||
| Quick Ratio | 5.79 | ||
| Altman-Z | 6.54 |
F-Score5
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)54.52%
Cap/Depr(5y)46.98%
Cap/Sales(3y)0.65%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-114.63%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-160%
EPS Next Y-172.42%
EPS Next 2Y-23.42%
EPS Next 3Y13.61%
EPS Next 5Y11.64%
Revenue 1Y (TTM)3.29%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%-20.82%
Revenue Next Year-22.17%
Revenue Next 2Y7.08%
Revenue Next 3Y14.93%
Revenue Next 5Y14.67%
EBIT growth 1Y-116.01%
EBIT growth 3Y25.22%
EBIT growth 5YN/A
EBIT Next Year-143.74%
EBIT Next 3Y-12.48%
EBIT Next 5Y-27.34%
FCF growth 1Y129.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.61%
OCF growth 3YN/A
OCF growth 5YN/A